Trial Profile
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs JNJ-67953964 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 03 Jul 2020 Status changed from active, no longer recruiting to completed.
- 06 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2019 Planned primary completion date changed from 11 Nov 2019 to 13 May 2020.